Oncolytics Biotech Files 6-K
Ticker: ONCY · Form: 6-K · Filed: Mar 5, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer, sec-filing
Related Tickers: ONCY
TL;DR
Oncolytics Biotech (ONCY) filed a 6-K, confirming foreign private issuer status and 20-F reporting.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on March 5, 2024, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations industry. This filing indicates they will file annual reports under Form 20-F.
Why It Matters
This filing confirms Oncolytics Biotech Inc.'s status as a foreign private issuer and its reporting obligations with the SEC, providing transparency for investors.
Risk Assessment
Risk Level: low — This is a routine filing confirming reporting status and not indicating any new material events or financial changes.
Key Numbers
- 001-38512 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Registrant
- 001-38512 (company) — SEC File Number
- 20240305 (date) — Filing Date
- Calgary, Alberta, Canada (location) — Company Headquarters
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report as a foreign private issuer and indicate that the registrant files annual reports under Form 20-F.
What is the company's name and location?
The company's name is Oncolytics Biotech Inc., located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
What is the SEC file number for Oncolytics Biotech Inc.?
The SEC file number is 001-38512.
What is the SIC code for Oncolytics Biotech Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Does this filing indicate any new financial results or material events?
No, this filing is a routine report of foreign private issuer status and does not disclose new financial results or material events.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-03-05 13:08:24
Filing Documents
- form6kgobletc5.htm (6-K) — 18KB
- oncygobletc5.htm (EX-99.1) — 29KB
- 0001129928-24-000012.txt ( ) — 47KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date March 5, 2024 Kirk Look Chief Financial Officer